<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="53202">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02413580</url>
  </required_header>
  <id_info>
    <org_study_id>GTI1305</org_study_id>
    <nct_id>NCT02413580</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations</brief_title>
  <official_title>A Multicenter, Prospective, Open-label, Non-controlled Clinical Trial to Assess the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Patients With Myasthenia Gravis Exacerbations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grifols Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grifols Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, prospective, open-label, non-controlled study to assess the efficacy
      and safety of an IV dose of 2 g/kg of IGIV-C in subjects with MG exacerbations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of a single dose course of IGIV-C treatment followed by 28-days of
      post-infusion assessments. The total duration of study participation for each subject is up
      to 28 ± 2 days. Approximately 50 subjects, ages 18 or greater, are planned to be enrolled in
      the study and receive a single, total dose of 2 g/kg of IGIV-C over 2 consecutive days (dose
      of 1 g/kg per day) across multiple centers in Argentina, Canada, Europe and South Africa.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in quantitative myasthenia gravis (QMG) scale score</measure>
    <time_frame>From Baseline (Day 0) to Day 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with clinical improvement assessed by QMG</measure>
    <time_frame>Baseline (Day 0) to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with clinical improvement assessed by MG-Activities of Daily Living (MG-ADL)</measure>
    <time_frame>Baseline (Day 0) to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with clinical improvement assessed by the MG Composite</measure>
    <time_frame>Baseline (Day 0) to Day 14</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Myasthenic Crisis</condition>
  <arm_group>
    <arm_group_label>IGIV-C Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>An IV dose of 2 g/kg of IGIV-C will be administered in subjects with myasthenia gravis exacerbations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IGIV-C</intervention_name>
    <description>an IV dose of 2 g/kg of IGIV-C will be administered as 2 doses of 1 g/kg on two consecutive days</description>
    <arm_group_label>IGIV-C Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must be willing and able to provide written informed consent (if applicable,
             a legally authorized representative may provide informed consent on behalf of the
             subject).

          -  Subjects who meet the clinical criteria for diagnosis of MG with an exacerbation
             defined as worsening of MG symptoms as defined by an Myasthenia Gravis Foundation of
             America (MGFA) classification IVb or V.

          -  Subjects on long-term (8 weeks) corticosteroid treatment for MG.

          -  Female subjects of child-bearing potential must have a negative test for pregnancy
             (human chorionic gonadotropin [HCG-based assay]).

          -  Subjects must be willing to comply with all aspects of the clinical trial protocol,
             including blood sampling and long-term storage of extra samples, for the entire
             duration of the study.

        Exclusion Criteria:

          -  Subjects who have received immune globulin treatment given by IV, subcutaneous or
             intramuscular route within the last 30 days.

          -  Subjects with documentation of a lack of clinical response to intravenous
             immunoglobulin (IVIg) therapy for MG.

          -  Subjects documented positive for antibodies directed against MuSK.

          -  Subjects with corticosteroid (CS) treatment initiated within the last 8 weeks or
             modified within the last 2 weeks.

          -  Subjects with plasma exchange (PLEX) within the last 30 days.

          -  Subjects with MG exacerbation attributable to change in medication or infection or
             evident infection as defined by, but not limited to, the presence of at least one of
             the following diagnostic features: 1) axillary temperature ≥38°C, 2) positive blood
             culture of infective microorganism, 3) white blood cell count &gt;12×10^9/L and
             differential white blood cell count of &gt;10% band neutrophils (&gt;1.2×10^9/L), and 4)
             pulmonary infiltrate with consolidation on chest X-ray. Alternatively, other signs
             and symptoms may be considered for the diagnosis of evident infection according to
             the Investigator's judgement.

          -  Subjects with inadequate venous access.

          -  Subjects with a history of anaphylactic reactions or severe reactions to any
             blood-derived product.

          -  Subjects with a history of intolerance to any component of the investigational
             products.

          -  Subjects with a documented diagnosis of thrombotic complications to polyclonal IVIG
             therapy in the past.

          -  Subjects with a history of recent (within the last year) myocardial infarction,
             stroke or uncontrolled hypertension.

          -  Subjects who suffer from uncontrolled congestive heart failure, embolism or
             documented electrocardiogram (ECG) changes indicative of myocardial ischemia or
             atrial fibrillation.

          -  Subjects with current known hyperviscosity or hypercoagulable state.

          -  Subjects currently receiving anti-coagulation therapy.

          -  Subjects with a history of chronic alcoholism or illicit drug abuse (addiction) in
             the 12 months preceding the Baseline Visit.

          -  Subjects currently receiving, or having received within 3 months prior to the
             Baseline Visit, any investigational medicinal product or device.

          -  Subjects with a known Immunoglobulin A (IgA) deficiency and anti-IgA serum
             antibodies.

          -  Subjects with renal impairment (i.e., serum creatinine exceeds more than 1.5 times
             the upper limit of normal [ULN] for the expected normal range for the testing
             laboratory).

          -  Subjects with aspartate aminotransferase (AST) or alanine aminotransferase (ALT)
             levels exceeding more than 2.5 times the ULN for the expected normal range for the
             testing laboratory.

          -  Subjects with haemoglobin levels &lt;9 g/dL.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sandra Camprubi, PhD</last_name>
    <email>sandra.camprubi@grifols.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>AZ St Lucas Gent</name>
      <address>
        <city>Ghent</city>
        <state>East Flanders</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy De Koning</last_name>
      <email>secretariaat.neurologie@azstlucas.be</email>
    </contact>
    <investigator>
      <last_name>Jan De Bleecker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Dhondt</last_name>
      <email>cardiovpk.kn@vzwgo.be</email>
    </contact>
    <investigator>
      <last_name>Philip Van Damme</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Hulley</last_name>
      <email>Denise.Hulley@lhsc.on.ca</email>
    </contact>
    <contact_backup>
      <last_name>Wilma Koopman</last_name>
    </contact_backup>
    <investigator>
      <last_name>Michael Nicolle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Health Network (UHN) - Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eduardo Ng</last_name>
      <email>Eduardo.Ng@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Vera Bril</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montreal Neurological Institute and Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Eon</last_name>
      <email>victoria.c.eon@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Angela Genge</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Brno, Neurologicka klinika</name>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stanislava Toncrova</last_name>
      <email>stanislava.toncrova@fnbrno.cz</email>
    </contact>
    <investigator>
      <last_name>Josef Bednarik</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Ostrava, Neurologická klinika</name>
      <address>
        <city>Ostrava</city>
        <zip>70800</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petr Hon</last_name>
      <email>petr.hon@fnspo.cz</email>
    </contact>
    <investigator>
      <last_name>Petr Hon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vseobecna fakultni nemocnice v Praze</name>
      <address>
        <city>Prague</city>
        <zip>12808</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michaela Tyblova</last_name>
      <email>mtyblova@seznam.cz</email>
    </contact>
    <contact_backup>
      <email>myadisp@vfn.cz</email>
    </contact_backup>
    <investigator>
      <last_name>Michaela Tyblova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>East Tallinn Central Hospital</name>
      <address>
        <city>Tallinn</city>
        <zip>10138</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toomas Toomsoo</last_name>
      <email>toomas.toomsoo@itk.ee</email>
    </contact>
    <investigator>
      <last_name>Toomas Toomsoo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Moutarde</last_name>
      <email>moutarde.j@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Jean Pouget</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse - Hôpital Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurore Naudin</last_name>
      <email>naudin.a@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>David Brassat</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pest Megyei Flor Ferenc Korhaz</name>
      <address>
        <city>Kistarcsa</city>
        <zip>2143</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gyula Pánzél</last_name>
      <email>panczel@florhosp.hu</email>
    </contact>
    <investigator>
      <last_name>Gyula Pánzél</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Szabolcs-Szatmár-Bereg Megyei Kórházak és Egyetemi Oktatókórház</name>
      <address>
        <city>Nyíregyháza</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edit Muskoczki</last_name>
      <email>muskoczki@josa.hu</email>
    </contact>
    <investigator>
      <last_name>Peter Dioszeghy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Szeged, Faculty of Medicine</name>
      <address>
        <city>Szeged</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laszlo Vecsei</last_name>
      <email>vecsei@nepsy.szoteu-szeged.hu</email>
    </contact>
    <investigator>
      <last_name>Laszlo Vecsei</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zala Megyei Korhaz</name>
      <address>
        <city>Zalaegerszeg</city>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janos Nikl</last_name>
      <email>drnikl@zmkorhaz.hu</email>
    </contact>
    <investigator>
      <last_name>Janos Nikl</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Riga East Clinical University Hospital</name>
      <address>
        <city>Riga</city>
        <zip>LV-1038</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guntis Karellis</last_name>
      <email>guntis.karelis@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Guntis Karellis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pauls Stradins Clinical University Hospital</name>
      <address>
        <city>Riga</city>
        <zip>LV1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrejs Millers</last_name>
      <email>andrejs@stradini.lv</email>
    </contact>
    <investigator>
      <last_name>Andrejs Millers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magdalena Chylinska</last_name>
      <email>madziana500@wp.pl</email>
    </contact>
    <investigator>
      <last_name>Malgorzata Bilinska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institutul Clinic Fundeni</name>
      <address>
        <city>Bucuresti</city>
        <zip>22328</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Crisanda Vilciu</last_name>
      <email>crisandavalciu@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Crisanda Vilciu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean de Urgenta Targu-Mures</name>
      <address>
        <city>Targu Mures</city>
        <zip>RO540136</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rodica Ioana Balasa</last_name>
      <email>iipascu@redatronic.ro</email>
    </contact>
    <investigator>
      <last_name>Rodica Ioana Balasa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>State Budgetary Institution of Healthcare of Nizhniy Novgorod region. Nizhniy Novgorod Regional Clinical Hospital named after N.A.Semashko</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603126</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Gustov</last_name>
      <email>gustovav@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Alexander Gustov</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>- Saint-Petersburg State Budgetary Institution of Healthcare. City Multi-field Hospital # 2</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>357538</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dmitry Rudenko</last_name>
      <email>dmrud_h2@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Fatima Stuchevskaya</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>State Budgetary Institution of Healthcare &quot;Samara Regional Clinical Hospital. V.D.Seredavin</name>
      <address>
        <city>Samara</city>
        <zip>443095</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadezhda Kuznetsova</last_name>
      <email>nadiv35@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Irina Poverennova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groote Schuur Hospital,</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fiona Drummond</last_name>
      <email>fionad@zsd.co.za</email>
    </contact>
    <investigator>
      <last_name>Jeannine Heckmann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Latvia</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 25, 2016</lastchanged_date>
  <firstreceived_date>April 7, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Myasthenia Gravis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
